São Paulo, November 18, 2025 – Eurofarma, one of the largest pharmaceutical companies in Latin America, announces the launch of Rehidrat, its new high-performance isotonic line, developed to offer fast and effective hydration in different consumption situations, whether in sports practice, such as street running, or in daily activities. The arrival of the product reinforces the company's bet on the OTC (Over The Counter) market, which since 2021 has brought products from different categories into its portfolio, such as Valda lozenges and the personal care brand OAZ.

"With Rehidrat, we reinforce our commitment to innovation and quality, offering the consumer a superior solution for hydration, aligned with health and performance trends. This launch is an important step in consolidating Eurofarma as a protagonist in the OTC market," says Alberto Kato, Commercial Director for Rehidrat at Eurofarma.

The OTC and Isotonic Market
The OTC product market in Brazil has consolidated as one of the main expansion fronts for the pharmaceutical industry, driven by the increase in self-care and the search for practical solutions for health and well-being. In 2024, the segment showed a growth of 12%, moving R$ 19.24 billion in the country, according to data from Abrafarma.

Within this context, the oral hydration market — where Rehidrat is positioned — demonstrates significant potential. Considering combined data from IQVIA (pharmacy channel) and Scanntech (food channel), the segment moved R$ 1.4 billion in the cumulative period from July 2024 to July 2025, reinforcing the strategic opportunity for Eurofarma to act as a protagonist in this category.

Rehidrat brings an innovative formulation proposal:

• Exclusive HidraMax Formula: it is the only product on the market that brings the complete combination of ingredients, being the precise balance of electrolytes and glucose for immediate cellular rehydration.
• Preservative-free, with natural flavors of Dragon Fruit with Lemon, Grape, and Tangerine.
• Ergonomic packaging with a spill-proof nozzle, designed for safe consumption during physical exercise.
• The only product in this market that is totally sterile.

Eurofarma Expansion in OTC
Eurofarma's OTC division has stood out since 2021, with strategic acquisitions and launches that expanded its presence in categories such as oral health, personal care, supplements, and food. In 2024 alone, the OTC unit grew 23.5%, reaching almost R$ 500 million in revenue. Brands like Valda, OAZ, and Fixaderme are already references in the market and are part of the company's growth strategy, which seeks to offer complete solutions for health and well-being.

Until the beginning of 2026, the company has several activations planned for Rehidrat, such as sponsorship of the Track & Field race in November, the São Silvestre in December, the final stages of the 2025 Stock Car, and actions on beaches in Rio de Janeiro and parks in São Paulo. To follow everything about the new brand, visit: instagram.com/rehidrat_oficial/.

About Eurofarma
Founded in 1972, Eurofarma operates in the health sector with the production and marketing of products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as medical prescription, generics, hospital, oncology, OTC, personal care, and animal health, in addition to providing production services to third parties. With broad coverage of therapeutic classes, the portfolio comprises more than 4,000 SKUs, serving practically all medical specialties. Leader in medical prescription in Brazil, where it also holds the vice-leadership in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and leadership in the region's retail. It also maintains operations in the USA and Africa, counting in total more than 13.5 thousand employees and 11 factories, and accounted for 600 million units produced in 2024. In the same year, the company invested more than R$ 800 million in innovation projects and achieved net revenue exceeding R$ 11 billion.

Press Information
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - +55 11 97644-4496 (iza.franca@gaspar.com.br)
Guilherme Gaspar - +55 11 98285-6000